What is the development status of Tectin™?
The Phase IIa result showed Tectin™ to be meaningful as it relieved chronic pain in 71% of cancer pain patients. The Company has recently terminated its Canadian Phase IIb/III trial after receiving an unfavourable interim analysis and is now reviewing the data to determine the next course of action. Tectin™ has also been cleared for a severe non-malignant chronic pain study in Canada and has begun its Chinese Phase II analgesic study.
